PharmApprove is part of SSI Strategy and provides strategic communications support for pharmaceutical and biotech companies preparing for high-stakes FDA and EMA meetings.
PharmApprove integrates with SSI Strategy’s capabilities to support meeting preparation and other high-stakes meetings. PharmApprove reports over 25 years of experience and having guided more than 200 clients through high-stakes meetings.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company provides scientific support and project management, and uses data visualization design to distill complex information into clear messages.
Source: LinkedIn company description · Retrieved October 13, 2026
Experts collaborate with clients to craft narratives and communication strategies that showcase their innovations.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.Snapshot: September 26, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 4, 2026, September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 20, 2026, September 26, 2026, September 27, 2026, September 28, 2026, September 30, 2026, October 7, 2026, October 8, 2026, October 9, 2026 and October 10, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.